Pancreatic Neuroendocrine Tumors (PNETs)
- Home
- Solutions
- Other Gastrointestinal Disorders
- Pancreatic Neuroendocrine Tumors (PNETs)
Pancreatic neuroendocrine tumors (PNETs) are rare and diverse types of tumors of the pancreas which also differ in their potential to become malignant. At Protheragen, we have developed a unique one-stop service for drug development geared towards PNETs and other rare diseases. We provide integrated solutions for all phases of the discovery and development of a drug, including target and molecular profile discovery, preclinical validation, and market conversion support.
Pancreatic neuroendocrine tumors (PNETs) are a type of neuroendocrine tumor (NET) that occurs mostly in the pancreas and the upper small intestine, and as such, are often synonymously referred to as pancreatic endocrine tumors (PETs). Despite PNETs accounting for only 1% to 2% of pancreatic neoplasms and having an incidence rate of under one in one hundred thousand individuals a year, their occurrence is on the rise.
Fig.1 Mechanism of action various therapeutics. (Giri, S., and Sahoo, J., 2024)
Neuroendocrine tumors of the pancreas arise from the diffuse neuroendocrine system within the pancreas. Mutations in MEN1, DAXX/ATRX, and other genes of the mammalian target of the rapamycin pathway have almost always been associated with sporadic PNETs. Inherited forms of PNETs have been associated with von Hippel-Lindau syndrome, multiple endocrine neoplasia type 1, neurofibromatosis type 1, and tuberous sclerosis complex.
Fig.2 Current challenges in PNETs research. (Mpilla, G. B., et al., 2020) | Drug Names | Mechanism of Action | Targets | NCT Number | Research Phase |
| Everolimus | This decreases protein synthesis, cell proliferation, and angiogenesis and acts mTOR inhibitor. | mTOR | / | Approved |
| Sunitinib | It inhibits several RTK's which, appear to be responsible for neoplastic cell growth, pathologic angiogenesis, and cancer metastasis. | Tyrosine kinase | / | Approved |
| Lanreotide | A long-acting inhibitor of hormone secretion and a modulator of cell proliferation signals in PNETs. | SSTR | NCT02288377 | Phase II/III |
| Surufatinib | A new small molecular inhibitor aimed to target tumor-associated angiogenesis and immune evasion in PNETs. | CSF-1R | NCT02589821 | Phase III |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Integrating advanced research and new technologies to tackle the specific issues of PNETs, we stay at the forefront of scientific developments. Our oncology experts and scientists design individualized programs that include comprehensive diagnostic and therapeutic modalities and disease model development, along with extensive pharmacokinetic investigations and safety evaluations that seek novel therapeutic targets and innovative drug candidates.
The use of animal models also improves understanding of drug safety and efficacy while expediting the bench-to-bedside process. Our company integrates modern technologies as well as expertise to offer tailored animal model development services solutions aimed towards meeting client expectations regarding drug research and development.
These involve implanting tumor tissues from PNETs individuals directly into immunocompromised mice.
Optional models: Patients-derived xenografts, other models.
The genetically engineered models by manipulating specific genes involved in tumor development.
Optional models: Rip1-Tag2 transgenic model, Rip1-Tag5 transgenic model, other models.
Select Protheragen as your partner in PNETs drug development, and take advantage of our pioneering research and innovation, sophisticated technology, and all-encompassing assistance to expedite the development of new therapies. Feel free to reach out to us anytime regarding our services.
References
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.